Hisham Alshadfan

Mr. Hisham Alshadfan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Medicine
Verified
Journal Article
Open access
HAHisham Alshadfan
Hisham Alshadfan
HMHyder Mirghani
Hyder Mirghani
TATariq Alrasheed
Tariq Alrasheed
MAMansuor A. Alanazi
Mansuor A. Alanazi
AAAmirah M M Alatawi
Amirah M M Alatawi
MAMuhammad Nazrul Hakim Abdullah
Muhammad Nazrul Hakim Abdullah
Gastrointestinal (GI) side effects from metformin often limit its use and can impact patient quality of life (QoL) and satisfaction. The extended-release (XR) formulation is thought to cause fewer GI adverse events than immediate-release (IR) metformin, potentially improving tolerability, treatment satisfaction, and adherence. To compare metformin IR vs XR in terms of GI tolerability (incidence of GI side effects), patient-reported QoL, and medication satisfaction over 6 months in Saudi patients with type 2 diabetes. In a prospective cohort of 119 newly diagnosed patients with type 2 diabetes (62 on IR, 57 on XR), we tracked GI adverse events using a standardized questionnaire at baseline and 6-month follow-up. Diabetes-specific QoL was measured with the diabetes therapy-related quality of life questionnaire (DTR-QOL), and treatment satisfaction was assessed with the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2). Metformin XR was associated with significantly better GI tolerability. By 6 months, 45.2% of IR patients and only 24.5% of XR patients reported any GI side effect ( P <.05). Rates of bothersome symptoms, such as diarrhea, were notably higher in the IR group. Patients on XR reported fewer interruptions of therapy due to GI upset. The DTR-QOL global score improved in both groups ( P <.05), but there was no significant difference in total DTR-QOL scores between groups ( P = .390). The OHA-Q ver. 2 global score improved in both groups ( P <.05), but the XR group had higher scores in domains related to satisfaction (median treatment satisfaction domain score 100 vs 77.78 for IR, P < .05), with a significant difference in OHA-Q ver. 2 global score (92.59 vs 86.31 for IR; P <.05). Metformin XR demonstrated superior GI tolerability, which translated into improved treatment satisfaction compared to IR. While the overall quality of life related to diabetes management improved similarly with both, the XR formulation reduced side effect burden, and the lower daily dosing led to higher patient-reported satisfaction. These findings support the use of metformin XR to enhance tolerability and adherence, potentially leading to improved long-term outcomes.

18 August 2024 in Medical Sciences
Verified
Journal Article
Open access
PDF file
BABadriah Alanazi
Badriah Alanazi
G. MuhiuddinG. Muhiuddin
G. Muhiuddin
YAYAZEED ALBALAWI
YAZEED ALBALAWI
KAKhalid of Alhazmi
Khalid of Alhazmi
OAOthman Alzahrani
Othman Alzahrani
MZMOHAMMAD ZUBAIR
MOHAMMAD ZUBAIR
The increasing prevalence of antibiotic resistance, driven by the production of extended-spectrum beta-lactamases (ESBLs), presents a critical challenge to current medical treatments, particularly in clinical settings. Understanding the distribution and frequency of ESBL-producing bacteria is essential for developing effective control strategies. This study investigated the antibiotic resistance and extended-spectrum beta-lactamase (ESBL) production in bacterial isolates in clinical and non-clinical (food) specimens in Tabuk, KSA. A total of 57 bacterial isolates were analysed, with E. coli and Pseudomonas sp. being the most prevalent. High resistance rates were observed, particularly against third-generation cephalosporins in clinical isolates. ESBL screening revealed a significant prevalence in clinical samples (58.3%), with E. coli showing the highest positivity. Conversely, only a low percentage of food isolates were ESBL positive. Molecular analysis confirmed the presence of various ESBL genes, with blaCTX-M being the most frequent, predominantly found in clinical isolates. This study highlights the concerning levels of antibiotic resistance and ESBL production in the region, emphasising the need for effective infection control measures and prudent antibiotic use.

11 December 2025 in Journal of Taibah University Medical Sciences
Verified
Journal Article
Open access
HAHisham Alshadfan
Hisham Alshadfan
HMHyder Mirghani
Hyder Mirghani
TATariq Alrasheed
Tariq Alrasheed
MAMuhammad Nazrul Hakim Abdullah
Muhammad Nazrul Hakim Abdullah
Metformin, the first-line treatment for type 2 diabetes mellitus (T2DM), is available in both immediate-release (IR) and extended-release (XR) formulations. Limited data exist comparing their effects on glycemic control and insulin resistance among Saudi patients. This study aims to evaluate the impact of metformin IR versus XR on glycated hemoglobin (HbA1c), fasting blood glucose (FBG), fasting serum insulin (FSI), and insulin resistance (HOMA-IR) in newly diagnosed Saudi T2DM patients. In a 6-month prospective cohort study at a Saudi diabetes center, 119 adults with newly diagnosed T2DM (62 on metformin IR, 57 on metformin XR) were followed. Glycemic parameters (HbA1c, FBG) and insulin resistance indices (FSI, HOMA-IR) were measured at baseline and after a 6-month follow-up. Within-group changes were assessed, and outcomes were compared between the IR and XR groups. Both formulations significantly improved glycemic control from baseline. HbA1c was reduced from 7.3 % at baseline to ∼6.5 % with metformin XR, versus ∼7.6 %–∼7.2 % with metformin IR. XR achieved a greater adjusted mean HbA1c reduction by 31 % than IR (p < 0.05). FBG improved in both groups with no significant statistical difference between groups (p = 0.111). Despite better glycemic declines with XR, FSI and HOMA-IR improved substantially with no statistically significant difference between groups (p > 0.05). In newly diagnosed Saudi patients with T2DM, metformin XR showed better reduction in long-term glycemic control compared to IR, while both formulations similarly reduced insulin levels and resistance. XR's enhanced glycemic efficacy, achieved without differences in insulin resistance effects, may reflect improved adherence and sustained drug delivery.

1 May 2025 in Edelweiss Applied Science and Technology
Verified
Journal Article
Open access
PDF file
HAHisham Alshadfan
Hisham Alshadfan
HMHyder Mirghani
Hyder Mirghani
TATariq Alrasheed
Tariq Alrasheed
AUArmania N Urdin
Armania N Urdin
MAMuhammad Nazrul Hakim Abdullah
Muhammad Nazrul Hakim Abdullah
Diabetes mellitus is common globally, and the Arab countries are no exception. Oral hypoglycemic agents are major pillars of diabetes management. The Oral Hypoglycemic Agent Questionnaire Version 2 (OHA-Q ver. 2) is unavailable in Arabic. Therefore, the study's goal was to validate the questionnaire for use among patients with diabetes in Saudi Arabia. Thirty patients with diabetes were randomly selected from those attending regular follow-ups at the King Fahd Specialist Hospital - Diabetes Center in Tabuk, Saudi Arabia. The study took place in March and April 2023. A structured questionnaire was utilized, incorporating sociodemographic data and the OHA-Q ver. 2. The questionnaire's validity and reliability were evaluated through forward and backward translation, expert review, and Cronbach's Alpha analysis. The results showed that a total of 30 diabetic patients participated in the questionnaire validation, with 60% being female, a mean age of 51.1 ± 14.056 years, and 94% diagnosed with type 2 diabetes. The internal consistency of the OHA-Q ver. 2 was highest for the "treatment convenience" subscale (0.83) and lowest for "satisfaction" (0.78). The overall content validity score was 0.875, and Cronbach’s Alpha for reliability was 0.88. The Arabic version of the OHA-Q ver. 2 has proven to be a valid and reliable tool for diabetic patients in Arab countries.

1 July 2023 in International Journal of Life Science and Pharma Research
Verified
Journal Article
Open access
HAHisham Alshadfan
Hisham Alshadfan
MAMarai Alamri
Marai Alamri
HMHyder Mirghani
Hyder Mirghani
SASamar Aljohani
Samar Aljohani
MAMansuor Alanazi
Mansuor Alanazi
MAMuhammad Nazrul Hakim Abdullah
Muhammad Nazrul Hakim Abdullah
Metformin is the first-line antidiabetic medication, and face-to-face comparisons between immediate-release and extended-release are scarce. The current meta-analysis aimed to compare metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. We searched PubMed, Cochrane Library, and the first 100 articles in Google Scholar from inception until September 2022. Studies were eligible if they were randomized controlled trials and compared metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. The keywords used were metformin immediate-release, extended-release, glycated hemoglobin, HbA1c, high-density lipoproteins, low-density lipoproteins triglycerides, total cholesterol, adverse effects, and side effects. The retrieved data were exported to an Excel sheet detailing the authors' names, the country of origin of the study, the number of patients and control subjects, and the total number of events in the interventional and control groups. No significant statistical difference was found between metformin immediate-release and metformin extended-release regarding the reduction of HbA1c, overall adverse effects, low-density lipoproteins, and high-density lipoproteins; odd ratio, 0.08, 95% CI, -0.14-0.29; 1.34, 95% CI, 0.86-2.08; -0.03, 95% CI, -0.22-0.17; and -0.26, 95% CI, -1.32-0.80 respectively. Metformin immediate-released reduced total cholesterol better than the extended-release; odd ratio, -2.35, 95% CI, -2.57-2.12. However, a paradox was observed regarding triglycerides (increment on extended-release and reduction with extended-release); odd ratio, -0.36, 95% CI, -0.44-0.28. No significant differences were found between the two formulations except for a better triglyceride reduction and total cholesterol in the immediate-release arm. Keywords: , , , ,

19 December 2025 in Pan African Medical Journal
Verified
Journal Article
Open access
HAHisham Alshadfan
Hisham Alshadfan
HMHyder Mirghani
Hyder Mirghani
TATariq Alrasheed
Tariq Alrasheed
MAMansuor Alanazi
Mansuor Alanazi
MAMuhammad Nazrul Hakim Abdullah
Muhammad Nazrul Hakim Abdullah
Introduction: dyslipidemia and obesity frequently accompany type 2 diabetes, contributing to cardiovascular risk. Metformin, beyond its effects on glycemic control, can also influence lipid metabolism and weight. Immediate-release (IR) and extended-release (XR) metformin may have differential effects on lipid profile and anthropometric measures. The study aimed to compare the effects of metformin IR versus XR on lipid parameters and body measurements in patients with type 2 diabetes in Saudi Arabia. Methods: a prospective 6-month cohort study included 119 newly diagnosed type 2 diabetes patients (62 on metformin IR and 57 on metformin XR) at a Saudi hospital. Fasting lipid profile (T-Chol, TGs, HDL-C, and LDL-C) and body weight/BMI were measured at baseline and after 6 months of metformin treatment. Within-group changes and between-group differences were analysed. Results: both groups showed modest improvements in their lipid profile. Metformin XR use was associated with a greater reduction in total cholesterol (-7.8% vs. -5.8% with IR) and LDL-C (-8.7% vs. -5.7% with IR). After 6 months, mean LDL-C was significantly lower in the XR group (102.3 ± 37.5 mg/dL) compared to the IR group (116.9 ± 36.0 mg/dL, p=0.032). Triglyceride and HDL-C levels changed minimally and were similar between groups. Neither IR nor XR had a significant impact on body weight or BMI: both groups remained essentially weight-neutral (average weight change <1 kg over 6 months). Final mean BMI was 30.4 ± 5.9 kg/m² in IR vs. 29.8 ± 4.7 kg/m² in XR (no significant difference). Conclusion: metformin XR was associated with short-term benefits in reducing total and LDL cholesterol levels compared to IR, likely attributable to more stable plasma drug concentrations that enhance lipid metabolism. Both formulations exhibited similar effects on triglycerides, HDL cholesterol, and body weight, reaffirming metformin's overall neutral impact on weight. These findings suggest that metformin XR may offer a marginal reduction in cardiovascular risk through superior LDL cholesterol lowering, while preserving the weight-neutral profile characteristic of metformin therapy.